Clinical Trials and Research Roundup | Doctors: Ivermectin Can Help Treat COVID: Will Anyone Listen?

Doctors: Ivermectin Can Help Treat COVID: Will Anyone Listen?

 

Introducing the Physicians for Civil Defense: Prominent Doctors Know #Ivermectin can Help Treat COVID-19: Will Anyone Listen?
A group calling itself Physicians for Civil Defense as it turns out is a group of physicians TrialSite Knows very well. In fact, they include Dr. Jacques Rajter of Fort Lauderdale, Florida, co-principal investigator and author of the ICON study evidencing the efficacy and safety of ivermectin as a treatment for COVID-19. The group recently presented at the U.S. Senate Homeland Security and Government Affairs Committee discussing possible safe and economical treatment for both prophylaxis and treatment for COVID-19: namely ivermectin. 

Sanofi & GSK #Vaccine Reagent Mistake Will Cost Hundreds of Millions & 4-5 Month Delay During Pandemic:
An incredibly costly mistake will delay the Sanofi SA and GlaxoSmithKline PLC COVID-19 vaccine by several months, complicating plans by developed economies in America and Europe for greater numbers of inoculations. Due to mishaps with manufacturing processes, volunteers in studies were actually administered lower doses than the clinical trial protocol directed. Now, according to Sanofi, the teams will have to reformulate the vaccine and go through the process of needing to restart the clinical trials in February 2021. With an estimate of four to five months in the middle of a pandemic, this leads to an incredibly disappointing reality measured not only in enormous costs but also an adverse impact on the mission to combat COVID-19. Initially thinking the two companies could have a regulatory approved product by the first half of 2021, they now estimate the last quarter of 2021—about a year from now. Both of these European pharmaceutical companies received $2.1 billion of U.S. taxpayer money from Operation Warp Speed in a bid to accelerate the testing, production and ultimate distribution of this vaccine candidate. Read the article here

Health Care Workers Hesitant About #COVID-19 Vaccines:
A new article from National Public Radio, “Some Health Care Workers Are Wary Of Getting COVID-19 Vaccines,” posits that even though these front-line high-risk folks are most in need of a vaccine, the rapidity of the development process and the appearance of political interference has left many “on the fence.” A large number of these health care workers have been expressing hesitancy about receiving COVID-19 vaccines, and the CDC has made dealing with this uncertainty a priority. According to a CDC survey, 63% of medical care workers polled over the last few months say they would get a vaccine if and when one is available. “I’m really hesitant about it,” offers Kida Thompson, family physician in El Paso, Texas. With her home town undergoing a large surge in COVID-19 cases, the doctor thinks that in the long run a key ingredient to ending the pandemic will be a vaccine. Yet she is not fully certain she will take such a shot. “The flu vaccine has been around for a while, its efficacy has been proven, the side effects have been proven, and they are usually minimal,” she opines.

Health Care Workers Hesitant About COVID-19 Vaccines (trialsitenews.com)

 

 
 

Responses

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  1. Prominent doctors say Ivermectin will help treat CO-19 is anyone listening????? they did not add in the mean time thousands die(They were kind) when will the madness end?????

  2. It’s time do judicialize this subject matter in order to force an analyse of the studies by the responsible organs. They are clearly being sabotaged, so like de physicians…

  3. The use of ivermectin in Covid19 is still very controversial.
    First, because the study with ivermectin in vitro, demonstrated in vitro action against the coronavirus, but with cytotoxic action (it killed the cells too), and ivermectin was used in a dose equivalent to 10,000 to 20,000 times the usual. The drug does not appear to have good penetration into pneumocytes.
    Second, in this study, the results demonstrate the absence of clinical benefit with the use of ivermectin in the usual dose in severe cases of Covid-19. The authors point out, however, that the drug was administered late and that a dose of 200 mcg / kg generates serum levels less than necessary for action against SARS-CoV-2 in vitro. Very high doses of ivermectin have not yet been evaluated for safety in clinical trials.
    https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242184